Clinical trial
A First in Human, Randomized, Double-blind, Single Ascending Dose, Phase Ia Clinical Study to Assess the Safety, Tolerability and Pharmacokinetic Parameters of CN128 Tablets in Thalassemia Patients Aged 16 and Above
NCT03673085 is registered in ClinicalTrials.gov with Hangzhou Zede Pharma-Tech Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A First in Human, Randomized, Double-blind, Single Ascending Dose, Phase Ia Clinical Study to Assess the Safety, Tolerability and Pharmacokinetic Parameters of CN128 Tablets in Thalassemia Patients Aged 16 and Above
- Lead sponsor
- Hangzhou Zede Pharma-Tech Co., Ltd.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- January 5, 2018
- Completion date
- December 17, 2019
- Enrollment
- 32 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.